

Individuals exposed to a person with infectious multidrug-resistant or rifampicin-resistant (MDR-RR) tuberculosis are at risk of developing tuberculosis disease. Historically, insufficient empirical evidence for preventive treatment in this group has permitted inadequate guidance for clinical decision making. However, several high-quality studies have been published detailing preventive treatment options for these contacts at high risk. In this Review, we discuss the management of individuals exposed to patients with infectious MDR-RR tuberculosis.
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet
Infectious Diseases
|15th Jan, 2026
|The Lancet